Inflammatory bowel disease: Crohn's disease and ulcerative colitis;Chronisch entzündliche Darmerkrankungen: Morbus Crohn und Colitis ulcerosa

Deutsches Arzteblatt International

Volumn 113, Issue 5, 2016, Pages 72-81

  Wehkamp, Jan ^a   Götz, Martin ^a   Herrlinger, Klaus ^b   Steurer, Wolfgang ^c   Stange, Eduard F ^c  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Asklepios Klinik Nord Heidberg   (Germany)

^c ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; INFLAMMATORY BOWEL DISEASE; ABDOMINAL SURGERY; DIAGNOSTIC IMAGING; EUROPE; EVIDENCE BASED MEDICINE; HUMAN; INFLAMMATORY BOWEL DISEASES; LABORATORY TECHNIQUE; META ANALYSIS; PREVALENCE; PROCEDURES; TREATMENT OUTCOME;

ANTIINFLAMMATORY AGENT;

ANTI-INFLAMMATORY AGENTS; CLINICAL LABORATORY TECHNIQUES; DIAGNOSTIC IMAGING; DIGESTIVE SYSTEM SURGICAL PROCEDURES; EUROPE; EVIDENCE-BASED MEDICINE; HUMANS; INFLAMMATORY BOWEL DISEASES; PREVALENCE; TREATMENT OUTCOME;

EID: 84964992849     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2016.0072     Document Type: Article

References (39)

1. Stange EF: Entzündliche Darmerkrankungen. Stuttgart: Schattauer Verlag 2015.
2. Buderus, S, Scholz D, Behrens R, et al.: Inflammatory bowel disease in pediatric patients-characteristics of newly diagnosed patients from the CEDATA-GPGE registry. Dtsch Arztebl Int 2015; 112: 121-7.
3. Molodecky NA, Soon IS, Rabi DM, et al.: Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46-54.
4. Preiss JC, Bokemeyer B, Buhr HJ, et al.: Updated German clinical practice guideline on "Diagnosis and treatment of Crohn's disease". Z Gastroenterol 2014; 52: 1431-84.
5. Dignass A, Preiss JC, Aust DE, et al.: Updated German guideline on diagnosis and treatment of ulcerative colitis. Z Gastroenterol 2011; 49: 1276-341.
6. van Assche G, Dignass A, Panes J, et al.: The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 2010; 4: 7-27.
7. Dignass A, Van Assche G, Lindsay JO, et al.: The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010; 4: 28-62.
8. Dignass A, Eliakim R, Magro, et al.: Second European evidencebased consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis 2012; 6: 965-90.
9. Dignass A, Lindsay JO, Sturm A, et al.: Second European evidencebased consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012; 6: 991-1030.
10. Rosenstiel P, Sina C, Franke A, Schreiber S: Towards a molecular risk map-recent advances on the etiology of inflammatory bowel disease. Semin Immunol 2009; 21: 334-345.
11. Duchmann R, May E, Heike M, et al.: T cell specificity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans. Gut 1999; 44: 812-8.
12. Moussata D, Goetz M, Gloeckner A, et al.: Confocal laser endomicroscopy is a new imaging modality for recognition of intramucosal bacteria in inflammatory bowel disease in vivo. Gut 2011; 60: 26-33.
13. Wehkamp J, Fellermann K, Herrlinger KR, Bevins CL, Stange EF: Mechanisms of disease: defensins in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 406-15.
14. VanDussen KL, Liu TC, Li D, et al.: Genetic variants synthesize to produce paneth cell phenotypes that define subtypes of Crohn's disease. Gastroenterology 2014; 146: 200-9.
15. Wehkamp J, Stange EF: Paneth's disease. J Crohns Colitis 2010; 4: 523-31.
16. Zundler S, Neurath MF: Immunopathogenesis of inflammatory bowel diseases: functional role of T cells and T cell homing. Clin Exp Rheumatol 2015; 33: 19-28.
17. Mosli MH, Zou G, Garg SK, et al.: C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease Patients: A systematic review and meta-analysis. Am J Gastroenterol 2015; 110: 802-19;
18. Rahier JF, Magro F, Abreu C, et al.: Second European evidencebased consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2014; 8: 443-68.
19. Annese V, Daperno M, Rutter MD, et al.: European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 2013; 7: 982-1018.
20. Tromm A, Bungani I, Tomsová E, et al.: Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease. Gastroenterology 2011; 140: 425-34.
21. Targan SR, Hanauer SB, van Deenter SJ, et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997; 337: 1029-35.
22. Hanauer SB, Sandborn WJ, Rutgeerts P, et al.: Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-33.
23. Sandborn WJ, Feagan BG, Rutgeerts P, et al.: Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013; 369: 711-21.
24. Akobeng AK, Gardener E: Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease. Cochrane Database Syst Rev 2005; (1): CD003715.
25. Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M: Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009; (1): CD000067.
26. Gordon M, Taylor K, Akobeng AK, et al.: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease. Cochrane Database Syst Rev 2014; (8): CD010233.
27. Marshall JK, Irvine EJ: Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther 1995; 9: 293-300.
28. Marteau P, Probert CS, Lindgren S, et al.: Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a ran - domised, double blind, placebo controlled study. Gut 2005; 54: 960-5.
29. Schmidt KJ, Herrlinger KR, Emmrich J, et al.: Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients. Aliment Pharmacol Ther 2013; 37: 129-36.
30. Laharie D, Bourreille A, Branche J, et al.: Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380: 1909-15.
31. Feagan BG, Rutgeerts P, Sands BE, et al.: Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699-710.
32. Feagan BG, Macdonald JK: Oral 5-aminosalicylic acid for main tenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012; 10: CD000544.
33. Rubin DT, Becker S, Siegler M: Ethical considerations for clinical trials in inflammatory bowel disease. Gastroenterol Hepatol 2014; 10: 37-41.
34. Indar AA, Efron JE, Young-Fadok TM: Laparoscopic ileal pouch-anal anastomosis reduces abdominal and pelvic adhesions. Surg Endosc 2009; 23: 174-177.
35. Fazio VW, Marchetti F, Church M, et al.: Effect of resection margins on the recurrence of Crohn's disease in the small bowel. A randomized controlled trial. Ann Surg 1996; 224: 563.
36. Fichera A, Michelassi F: Surgical treatment of Crohn's disease. J Gastrointest Surg 2007; 11: 791.
37. Michelassi F, Sultan S: Surgical treatment of complex small bowel Crohn disease. Ann Surg 2014; 260: 230-5.
38. Alós R, Hinojosa J: Timing of surgery in Crohn's disease: a key issue in the management. World J Gastroenterol 2008; 14: 5532-9.
39. Cohen JL, Strong SA, Hyman NH, et al.: Practice parameters for the surgical treatment of ulcerative colitis. Dis Colon Rectum 2005; 48: 1997-2009.